Stop by Booth #110 at Access USA to meet the Real Endpoints team! We're showcasing RE Assist, a tech-enabled platform that simplifies the process of finding copay assistance for Medicare patients.
read full article ›Seems like the biopharma industry, not just Caesar, should beware the ides of March. Yesterday, the Centers for Medicare & Medicaid Services updated its guidance for drug price negotiation under the Inflation Reduction Act clarifying that drugs with the same active ingredients will be groups together even if they are approved under different biologic license applications. That suggests that different formulations (say a sub-cue version of an infusion product developed earlier) would be subject to price negotiation at the earliest date of eligibility.
read full article ›